Nir Klein, Chief Executive Officer and Director of Silynxcom Ltd. (NASDAQ:SYNX), filed a Form 4 on November 3, 2026, disclosing three open-market purchases of Ordinary Shares totaling 50,149 shares acquired between October 29 and November 2, 2026.
BioStem Technologies, Inc. Chief Commercial Officer Barry Hassett filed a Form 4 on November 3, 2026, disclosing a transaction dated November 1, 2026, in which 253 shares of common stock were acquired through the vesting of restricted stock units at $0.00 per share.
Director Felix Villamil of First BanCorp /PR/ (NYSE:FBP) filed a Form 4 on November 3, 2026, disclosing two transactions in common stock dated October 30, 2026: a share withholding for tax purposes and a new restricted stock award.
Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp (NASDAQ:UTHR), filed a Form 4 on November 3, 2026, disclosing the exercise of 9,500 stock options and the sale of 9,500 shares of common stock on November 2, 2026, pursuant to a pre-arranged 10b5-1 …
Director Kevin M. Sheehan filed a Form 4 with the SEC on November 3, 2026, disclosing a transfer of 39,495 shares of Dave & Buster's Entertainment, Inc. common stock to a grantor retained annuity trust on November 2, 2026.
David J. Bates, Chief Operating Officer of XPO, Inc., filed a Form 4 on November 3, 2026, disclosing the sale of 2,615 shares of XPO common stock on November 2, 2026, under a pre-established Rule 10b5-1 trading plan.
Director Andrew C. Clarke filed a Form 4 with the SEC on November 3, 2026, disclosing a purchase of LKQ Corp common stock on October 30, 2026.
Director Michael Scott Powell filed a Form 4 with the SEC on November 3, 2026, disclosing a purchase of 10,000 shares of LKQ Corp common stock on November 2, 2026.
Patrick J. Christmas, Chief Strategy and Legal Officer of REGENXBIO Inc., reported the acquisition of 34,722 shares of common stock underlying a time-based restricted stock unit award, with a transaction date of November 1, 2026, in a filing submitted November 3, 2026.
REGENXBIO Inc. Chief Financial Officer Mitchell Chan filed a Form 4 on November 3, 2026, disclosing the acquisition of 24,305 shares of common stock underlying a time-based restricted stock unit award, with a transaction date of November 1, 2026.